newsfilter
← Latest News
GlobeNewswire·

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatmentSignificant regulatory and